Table 3.
Serum 25(OH)D | |||||||
---|---|---|---|---|---|---|---|
Adequate (>50 nmol/l) | Inadequate (30–50 nmol/l) | Deficient (<30 nmol/l) | |||||
Risk factor | OR | 95 % CI | OR | 95 % CI | OR | 95 % CI | P trend |
TC ≥ 200 mg/dl | |||||||
Sample size | 4025 | 1803 | 441 | ||||
Unadjusted | 1·00 | Reference | 1·38 | 1·14, 1·66 | 1·04 | 0·73, 1·48 | 0·471 |
Adjusted | 1·00 | Reference | 1·37 | 1·10, 1·71 | 0·99 | 0·66, 1·48 | 0·919 |
HDL-C ≤ 35 mg/dl | |||||||
Sample size | 4025 | 1803 | 441 | ||||
Unadjusted | 1·00 | Reference | 1·20 | 0·94, 1·54 | 1·09 | 0·70, 1·70 | 0·032 |
Adjusted | 1·00 | Reference | 1·64 | 1·22, 2·19 | 1·71 | 1·01, 2·90 | <0·001 |
LDL-C ≥ 130 mg/dl | |||||||
Sample size | 1605 | 741 | 189 | ||||
Unadjusted | 1·00 | Reference | 1·64 | 1·16, 2·31 | 1·49 | 0·83, 2·68 | 0·280 |
Adjusted | 1·00 | Reference | 1·80 | 1·19, 2·73 | 1·64 | 0·82, 3·28 | 0·523 |
Fasting TAG ≥ 150 mg/dl | |||||||
Sample size | 1633 | 772 | 199 | ||||
Unadjusted | 1·00 | Reference | 0·82 | 0·60, 1·13 | 0·54 | 0·28, 1·03 | 0·159 |
Adjusted | 1·00 | Reference | 1·20 | 0·82, 1·74 | 1·10 | 0·51, 2·35 | 0·112 |
Fasting glucose ≥ 100 mg/dl | |||||||
Sample size | 1171 | 650 | 190 | ||||
Unadjusted | 1·00 | Reference | 1·05 | 0·79, 1·40 | 0·91 | 0·56, 1·46 | 0·403 |
Adjusted | 1·00 | Reference | 1·40 | 1·00, 1.97 | 1·88 | 1·07, 3·28 | 0·19 |
HOMA-IR score ≥ 4.39 | |||||||
Sample size | 1159 | 645 | 188 | ||||
Unadjusted | 1·00 | Reference | 2·28 | 1·77, 2·94 | 3·04 | 2·12, 4·35 | <0·001 |
Adjusted | 1·00 | Reference | 2·55 | 1·89, 3·44 | 4·15 | 2·66, 6·47 | <0·001 |
TC, total cholesterol; HDL-C, HDL-cholesterol; LDL-C, LDL-cholesterol; HOMA-IR, homeostasis model assessment of insulin resistance; LOD, limit of detection.
Adjusted for age (continuous), gender (male, female), race and ethnicity (Mexican American, other Hispanic, non-Hispanic White, non-Hispanic Black, Other), poverty:income ratio (<1, ≥1), alcohol use (yes or no), and cotinine level (<0.01 ng/ml (LOD), 0.01–10 ng/ml, >10 ng/ml).